Novel d-Xylose Derivatives Stimulate Muscle Glucose Uptake by Activating AMP-Activated Protein Kinase α
摘要:
Type 2 diabetes mellitus has reached epidemic proportions; therefore, the search for novel antihyperglycemic drugs is intense. We have discovered that D-Xylose increases the rate of glucose transport in a non-insulin-dependent manner in rat and human myotubes in vitro. Due to the unfavorable pharmacokinetic properties Of D-Xylose we aimed at synthesizing active derivatives with improved parameters. Quantitative structure-activity relationship analysis identified critical hydroxyl groups in D-xylose. These data were used to synthesize various hydrophobic derivatives Of D-Xylose of which compound 19 the was most potent compound in stimulating the rate of hexose transport by increasing the abundance of glucose transporter-4 in the plasma membrane of myotubes. This effect resulted from the activation of AMP-activated protein kinase without recruiting the insulin transduction mechanism. These results show that lipophilic D-Xylose derivatives may serve as prototype molecules for the development of novel anti hyperglycemic drugs for the treatment of diabetes.
Novel d-Xylose Derivatives Stimulate Muscle Glucose Uptake by Activating AMP-Activated Protein Kinase α
摘要:
Type 2 diabetes mellitus has reached epidemic proportions; therefore, the search for novel antihyperglycemic drugs is intense. We have discovered that D-Xylose increases the rate of glucose transport in a non-insulin-dependent manner in rat and human myotubes in vitro. Due to the unfavorable pharmacokinetic properties Of D-Xylose we aimed at synthesizing active derivatives with improved parameters. Quantitative structure-activity relationship analysis identified critical hydroxyl groups in D-xylose. These data were used to synthesize various hydrophobic derivatives Of D-Xylose of which compound 19 the was most potent compound in stimulating the rate of hexose transport by increasing the abundance of glucose transporter-4 in the plasma membrane of myotubes. This effect resulted from the activation of AMP-activated protein kinase without recruiting the insulin transduction mechanism. These results show that lipophilic D-Xylose derivatives may serve as prototype molecules for the development of novel anti hyperglycemic drugs for the treatment of diabetes.
Saponin and sapogenol. XXVI. Steroidal saponins from the starfish Acanthaster planci L. (crown of thorns). 2. Structure of the major saponin thornasteroside A.
作者:ISAO KITAGAWA、MOTOMASA KOBAYASHI
DOI:10.1248/cpb.26.1864
日期:——
The major saponin named thornasteroside A (5) has been isolated from the whole body of starfish Acanthaster planci L. (crown of thorns). In order to facilitate the structural study, thornasteroside A (5) has been converted to a pentaglycoside (designated as dsp-1), which corresponds to a desulfated pregnane-type derivative of 5. On the bases of chemical reactions and physicochemical evidence, the structure of dsp-1 has been elucidated as 10. Based on the accumulated evidence in this and the preceding papers, the structure of thornasteroside A has been established as 20-hydroxy-6α-O-β-D-fucopyranosyl (1→2)-β-D-galactopyranosyl (1→4)-[β-D-quinovopyranosyl (1→2)]-β-D-xylopyranosyl (1→3)-β-D-quinovopyranosyl}-5α-cholest-9 (11)-en-23-on-3β-yl sodium sulfate (5).
A new steroidal glycoside phrygioside A and its aglycone from the starfish Hippasteria phrygiana
作者:E. V. Levina、A. I. Kalinovskii、P. V. Andriyashchenko、P. S. Dmitrenok、E. V. Evtushenko、V. A. Stonik
DOI:10.1007/s11172-005-0165-z
日期:2004.11
Three polyhydroxylatedsteroids were isolated from the Far-Eastern starfish Hippasteria phrygiana collected from the Sea of Okhotsk and were characterized as a new glycoside phrygioside A, viz., sodium (20R, 24S)-3β,4β,7α,8,15β,24-hexahydroxy-24-O-[3-O-methyl-β-D-xylopyranosyl-(1→2)-α-L-arabinofuranosyl]-5α-cholestan-6α-yl sulfate, its aglycone, and the already known marthasterone sulfate.
The present invention relates to pentose and pentose derivatives that are effective at increasing glucose transport in a non-insulin dependent manner, and to uses thereof for a) treating and/or preventing hyperglycemia; b) treating and/or preventing the complications of hyperglycemia; c) treating diabetes; d) increasing the rate of cellular glucose transport; e) increasing the rate of cellular glucose uptake; f) improving the ability of a subject to metabolize glucose; g) treating daily blood glucose fluctuations; h) reducing blood sugar levels; i) reducing the dosage of anti-diabetic medication needed for treatment of diabetes. The present invention further provides novel pentose derivatives having beneficial properties in terms of pharmacokinetics, to pharmaceutical compositions comprising these novel compounds and uses thereof.